5-Iodotubercidin

• Supplier: Tocris Bioscience
• Catalog: 1556
• Prices: $129.00
• Sizes: 1 mg
• Function Type: Inhibitor
• Cas Number: 24386-93-4
• Chemical Name: 5-Iodo-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• Formula: C11H13IN4O4
• Molecular Weight: 392.15
• Purity: >90 %
• Description: Potent adenosine kinase inhibitor (IC 50 = 26 nM). Also nucleoside transporter inhibitor (IC 50 values are < 25 nM, 7 μ M and 15 μ M for inhibition of [ 3 H]adenosine, [ 3 H]uridine and [ 3 H]formycin B uptake respectively). Strongly stimulates glycogen synthesis in hepatocytes via activation of glycogen synthase. Also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2 and PKC (IC 50 values are 0.4, 3.5, 5-10, 5-10, 10.9 and 27.7 μ M respectively). Decreases hippocampal DNA methylation through adenosine kinase inhibition in vivo .

Product References

Identification of the glycogenic compound 5-iodotubercidin as a general protein - Identification of the glycogenic compound 5-iodotubercidin as a general protein

Massillon D, Stalmans W, van de Werve G, Bollen M. Biochem J. 1994 Apr 1;299 ( Pt 1):123-8.

Effects of iodotubercidin on adenosine kinase activity and nucleoside transport - Effects of iodotubercidin on adenosine kinase activity and nucleoside transport

Parkinson FE, Geiger JD. J Pharmacol Exp Ther. 1996 Jun;277(3):1397-401.

Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure - Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure

Ugarkar BG, DaRe JM, Kopcho JJ, Browne CE 3rd, Schanzer JM, Wiesner JB, Erion MD. J Med Chem. 2000 Jul 27;43(15):2883-93.

Epigenetic changes induced by adenosine augmentation therapy prevent - Epigenetic changes induced by adenosine augmentation therapy prevent

Williams-Karnesky RL, Sandau US, Lusardi TA, Lytle NK, Farrell JM, Pritchard EM, Kaplan DL, Boison D. J Clin Invest. 2013 Aug;123(8):3552-63.